Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

UTHR – United Therapeutics Corporation

United Therapeutics Corporation
UTHR
$288.19
Name : United Therapeutics Corporation
Sector : Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Mark. Cap: $12,999,271,424.00
EPSttm : 25.1
finviz dynamic chart for UTHR
United Therapeutics Corporation
$288.19
1.38%
$3.92

Float Short %

3.67

Margin Of Safety %

24

Put/Call OI Ratio

0.73

EPS Next Q Diff

0.71

EPS Last/This Y

1.19

EPS This/Next Y

0.8

Price

284.18

Target Price

393.36

Analyst Recom

1.75

Performance Q

-7.71

Relative Volume

0.84

Beta

0.55

Ticker: UTHR




19 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-06-02UTHR325.690.960.057486
2025-06-03UTHR324.481.0111.257361
2025-06-04UTHR324.081.032.007450
2025-06-05UTHR319.961.041.937494
2025-06-06UTHR324.821.050.197555
2025-06-09UTHR328.451.013.457753
2025-06-10UTHR281.91.040.527917
2025-06-11UTHR276.840.810.7310847
2025-06-12UTHR286.060.820.4211030
2025-06-13UTHR283.390.780.3710906
2025-06-16UTHR288.630.760.3710823
2025-06-17UTHR287.160.750.1810946
2025-06-18UTHR291.80.740.7210874
2025-06-20UTHR290.690.740.8210894
2025-06-23UTHR286.30.780.137756
2025-06-24UTHR289.980.790.087921
2025-06-25UTHR285.930.760.238146
2025-06-26UTHR284.360.740.558379
2025-06-27UTHR284.230.730.258403
DateSymbolLastP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-06-02UTHR325.4525.8118.727.68
2025-06-03UTHR324.2025.863.227.68
2025-06-04UTHR324.0725.870.627.68
2025-06-05UTHR319.7125.443.627.68
2025-06-06UTHR325.8125.4110.927.68
2025-06-09UTHR328.4025.488.327.68
2025-06-10UTHR281.7625.4-229.127.68
2025-06-11UTHR276.6425.434.427.68
2025-06-12UTHR286.1425.4149.427.68
2025-06-13UTHR283.3325.449.827.63
2025-06-16UTHR288.6525.4112.727.63
2025-06-17UTHR286.9825.459.427.63
2025-06-18UTHR291.7225.4108.727.63
2025-06-20UTHR290.7525.464.227.63
2025-06-23UTHR286.2725.438.127.63
2025-06-24UTHR290.0525.499.727.63
2025-06-25UTHR285.9825.441.627.63
2025-06-26UTHR284.1025.457.027.63
2025-06-27UTHR284.1825.472.327.63
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-06-02UTHR-19.641.384.76
2025-06-03UTHR-19.751.384.76
2025-06-04UTHR-19.751.384.76
2025-06-05UTHR-19.751.384.76
2025-06-06UTHR-19.751.384.76
2025-06-09UTHR-19.311.404.76
2025-06-10UTHR-19.361.404.76
2025-06-11UTHR-19.361.404.26
2025-06-12UTHR-19.361.404.26
2025-06-13UTHR-19.361.404.26
2025-06-16UTHR-19.994.654.26
2025-06-18UTHR-19.424.654.26
2025-06-20UTHR-17.874.654.26
2025-06-23UTHR-17.871.424.26
2025-06-24UTHR-17.871.424.26
2025-06-25UTHR-18.091.424.26
2025-06-26UTHR-18.091.423.67
2025-06-27UTHR-17.261.423.67
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

Last Quarter Act. EPS

6.63

Avg. EPS Est. Current Quarter

7.06

Avg. EPS Est. Next Quarter

7.34

Insider Transactions

-17.26

Institutional Transactions

1.42

Beta

0.55

Average Sales Estimate Current Quarter

802

Average Sales Estimate Next Quarter

831

Fair Value

353.43

Quality Score

100

Growth Score

98

Sentiment Score

35

Actual DrawDown %

32

Max Drawdown 5-Year %

-32.6

Target Price

393.36

P/E

11.34

Forward P/E

9.66

PEG

1.83

P/S

4.28

P/B

1.88

P/Free Cash Flow

11.39

EPS

25.06

Average EPS Est. Cur. Y​

27.63

EPS Next Y. (Est.)

28.43

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

40.44

Relative Volume

0.84

Return on Equity vs Sector %

-6.1

Return on Equity vs Industry %

10.5

EPS 1 7Days Diff

EPS 1 30Days Diff

0.25

EBIT Estimation

72.3
United Therapeutics Corporation
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 1305
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. United Therapeutics Corporation was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
stock quote shares UTHR – United Therapeutics Corporation Stock Price stock today
news today UTHR – United Therapeutics Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch UTHR – United Therapeutics Corporation yahoo finance google finance
stock history UTHR – United Therapeutics Corporation invest stock market
stock prices UTHR premarket after hours
ticker UTHR fair value insiders trading